DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

National Institute of Allergy and Infectious Diseases Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Clinical Trial Implementation Cooperative Agreement (U01).

**Date:** October 27, 2016.

**Time:** 8:30 a.m. to 10:30 a.m.

**Place:** National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

**Contact Person:** Lynn Rust, Ph.D., Scientific Review Officer, National Institute of Allergy and Infectious Diseases, Room 3C43A National Institutes of Health, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892–9823, (240) 669–5069, lrust@niaid.nih.gov.

**Catalogue of Federal Domestic Assistance Program Nos.:** 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: August 29, 2016.

**Natasha M. Copeland,**
Program Analyst, Office of Federal Advisory Committee Policy.

**FR Doc. 2016–21121 Filed 9–1–16; 8:45 am**

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute on Drug Abuse Special Emphasis Panel; Identification of Genetic and Genomic Variants by Next-Gen Sequencing in Non-Human Animal Models (U01).

**Date:** September 23, 2016.

**Time:** 12:00 p.m. to 4:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

**Contact Person:** Jagadeesh S. Rao, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, Division of Extramural Research, National Institute on Drug Abuse, National Institutes of Health, 6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 20892, 301–443–9511, jrao@nida.nih.gov.

**Catalogue of Federal Domestic Assistance Program Nos.:** 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS

Dated: August 29, 2016.

**Natasha M. Copeland,**
Program Analyst, Office of Federal Advisory Committee Policy.

**FR Doc. 2016–21121 Filed 9–1–16; 8:45 am**

BILLING CODE 4140–01–P